

**Remarks**

Claims 1-23 are pending in the instant application. Applicants have amended claims 2-23 to more fully conform with U.S. practice and to remove multiple dependencies. Applicants have added new claim 24. The amendments do not constitute new matter.

The enclosed substitute specification in compliance with 37 CFR 1.121(b)(3) and 1.125 is for publication purposes and does not contain any markings. It includes a new first paragraph cross referencing the related priority applications.

Applicants provide herewith copies of the published international application, the international search report, the International Preliminary Report on Patentability and the Written Opinion of the International Preliminary Examining Authority. Also enclosed is the Form PTO-1449 listing the cited references and copies of the non-US citations.

Enclosed are copies of the signed 371 National Phase Power of Attorney and Declaration, which were both executed at the international stage.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry.

Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-24.

Respectfully submitted,



\_\_\_\_\_  
Yonggang Ji  
Registration No.: 53,073  
Agent for Applicants

**Customer No.: 22840**

GE Healthcare Bio-Sciences Corp.  
Patent Department  
800 Centennial Avenue  
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875  
Fax: (732) 457-8463